Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Enovis ( (ENOV) ) has provided an update.
Enovis Corporation announced that its management team would present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 4:30 p.m. PST (7:30 p.m. EST). The company made the presentation accessible to investors and other stakeholders via a live webcast on its website, with a replay and accompanying presentation materials also made available online later that day, underscoring Enovis’s ongoing investor-relations outreach and engagement with the healthcare investment community.
The most recent analyst rating on (ENOV) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Enovis stock, see the ENOV Stock Forecast page.
Spark’s Take on ENOV Stock
According to Spark, TipRanks’ AI Analyst, ENOV is a Neutral.
Enovis’s overall stock score is primarily impacted by its financial performance challenges, including profitability and liquidity issues. Technical analysis indicates bearish momentum, while valuation metrics reflect ongoing losses. Despite positive earnings call highlights, such as revenue growth and strategic initiatives, significant risks remain.
To see Spark’s full report on ENOV stock, click here.
More about Enovis
Average Trading Volume: 830,472
Technical Sentiment Signal: Sell
Current Market Cap: $1.65B
Learn more about ENOV stock on TipRanks’ Stock Analysis page.